India Pneumococcal Vaccine Market to Grow with a CAGR of 6.91% through 2030
Increasing
research & development is expected to drive the India Pneumococcal Vaccine
Market growth in the forecast period, 2026-2030.
According to
TechSci Research report, “India Pneumococcal Vaccine Market - By Region, Competition, Forecast & Opportunities, 2030F”, the India Pneumococcal
Vaccine Market stood at USD 32.52 Million in 2024 and is anticipated to grow
with a CAGR of 6.91% through 2030. The rising focus on research and development
(R&D) is playing a crucial role in advancing pneumococcal vaccines in
India, driving market growth through innovation, improved formulations, and
enhanced accessibility. With a growing disease burden and evolving bacterial
resistance, pharmaceutical companies and research institutions are investing in
next-generation vaccines to provide broader protection against pneumococcal
infections.
Indian vaccine
manufacturers, such as Serum Institute of India (SII) and Bharat Biotech, are
heavily engaged in R&D to develop cost-effective and high-efficacy
pneumococcal vaccines tailored to local needs. The launch of domestically
produced vaccines, like SII’s Pneumosil, has helped India reduce dependency on
expensive imports and expand immunization coverage. Additionally, the
introduction of new vaccine formulations, such as Abbott’s 14-valent
pneumococcal conjugate vaccine, demonstrates the impact of R&D on expanding
serotype coverage and enhancing protection.
Global
collaborations and technology transfers between Indian manufacturers and
international health organizations like WHO, Gavi, and UNICEF are further
accelerating research progress. These partnerships help fast-track clinical
trials, improve vaccine storage solutions, and ensure affordability for
large-scale immunization programs.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "India Pneumococcal Vaccine Market”
The India
Pneumococcal Vaccine Market is segmented into vaccine type, end use, regional distribution,
and company.
Based
on Vaccine Type, Pneumococcal Conjugate Vaccine have emerged as the fastest
growing segment in the India Pneumococcal Vaccine Market in the forecast period,driven
by its higher immunogenicity, broader serotype coverage, and strong government
backing. Unlike Pneumococcal Polysaccharide Vaccines (PPSV), PCVs induce a
stronger immune response, particularly in infants and high-risk populations,
making them a preferred choice for national immunization programs.
Based on Region,
East India have emerged as the fastest growing region in the India Pneumococcal
Vaccine Market in 2024. This rapid
growth is driven by increasing government immunization efforts, rising
awareness about pneumococcal diseases, and improved healthcare access in rural
areas. States like West Bengal, Bihar, Odisha, and Jharkhand have witnessed
significant expansion in vaccination programs, particularly under the Universal
Immunization Programme (UIP). The region has a high burden of pneumonia-related
child mortality, prompting targeted intervention strategies. Additionally,
infrastructure improvements, expanded cold chain facilities, and growing
penetration of private healthcare providers have further fueled vaccine uptake.
Major companies
operating in India Pneumococcal Vaccine Market are:
- Pfizer Inc.
- Merck & Co. Inc.
- GlaxoSmithKline PLC
- Novartis AG
- Serum Institute of India Pvt. Ltd.
- Panacea Biotec Limited
- Sanofi SA
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The increasing participation of private
healthcare providers, pharmaceutical companies, and corporate-backed
immunization programs is playing a crucial role in expanding access to
pneumococcal vaccines across India. With a rising preference for advanced
healthcare services, private hospitals, clinics, and diagnostic centers are
integrating premium vaccination services, making immunization more accessible
to urban and semi-urban populations”, said Mr. Karan Chechi, Research
Director of TechSci Research, a research-based management consulting firm.
“India Pneumococcal
Vaccine Market By Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal
Polysaccharide Vaccine), By End Use (Public Sector, Private Sector), By Region, Competition, Forecast & Opportunities, 2020-2030F”,
has evaluated the future growth potential of India Pneumococcal Vaccine Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in India Pneumococcal Vaccine Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com